Cyclacel Pharmaceuticals
$0.779876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.01 (-1.33%) Today
+$0.03 (+4.05%) As of 8:00 PM EST after-hours
Why Robinhood?
You can buy or sell CYCC and other stocks, options, ETFs, and crypto commission-free!
About CYCC
Cyclacel Pharmaceuticals, Inc. Common Stock, also called Cyclacel Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Employees
14
Headquarters
Berkeley Heights, New Jersey
Founded
1996
Market Cap
12.90M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
416.88K
High Today
$0.75
Low Today
$0.6733
Open Price
$0.73
Volume
442.38K
52 Week High
$1.18
52 Week Low
$0.2813
Collections
CYCC Earnings
-$0.20
-$0.17
-$0.14
-$0.11
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Mar 26, After Hours